MRU

The Pfizer Medical Research Unit (MRU), often referred to as the Clinical Research Unit (CRU), is a specialized division of Pfizer dedicated to conducting Phase 1 and early Phase 2 clinical trials. These units are state-of-the-art facilities designed to evaluate the safety, tolerability, and pharmacokinetics of new drug candidates in humans for the first time. With major locations in Brussels, Belgium, and New Haven, Connecticut, the MRU provides a controlled environment for high-complexity studies, including first-in-human trials and specialized biomarker assessments. The unit plays a critical role in Pfizer's global R&D strategy by accelerating the transition of innovative therapies from the laboratory to clinical proof-of-concept. By leveraging advanced medical technology and a dedicated team of clinical researchers, the MRU ensures rigorous data collection and participant safety across a wide range of therapeutic modalities.